Atazanavir launched in UK
2 May 2004. Related: Antiretrovirals.
Antiretrovirals
Tenofovir/FTC co-formulation application made to EMEA
2 May 2004. Related: Antiretrovirals.
Abacavir/3TC co-formulation available in expanded access
2 May 2004. Related: Antiretrovirals.
Treatment with generics: tolerability, safety and resistance
5 April 2004. Related: Antiretrovirals, Treatment access.
Drug levels can persist for more than two weeks after stopping efavirenz
3 April 2004. Related: Conference reports, Antiretrovirals, PK and drug interactions.
COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation
3 April 2004. Related: Conference reports, Antiretrovirals.
Studies of new pipeline drugs
3 April 2004. Related: Conference reports, Antiretrovirals.
Little benefit seen for treatment during acute infection
3 April 2004. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Gilead discontinues DAPD development
2 April 2004. Related: Antiretrovirals.
Abbott raises price of ritonavir in the US by over 400%
3 February 2004. Related: Antiretrovirals.
Development of T-1249 put on hold
3 February 2004. Related: Antiretrovirals.
Tenofovir/abacavir/3TC triple-nuke fails as maintenance regimen
3 February 2004. Related: Antiretrovirals.
New data on viral load ‘blips’ and the link to replication
3 February 2004. Related: Antiretrovirals.
Invirase and Fortovase: new dosing regimens approved by FDA
3 February 2004. Related: Antiretrovirals.
UK named-patient access to tipranavir
3 February 2004. Related: Antiretrovirals.
FDA labelling changes for indinavir (Crixivan)
3 February 2004. Related: Antiretrovirals.
Switching from efavirenz to nevirapine to avoid CNS side effects
1 December 2003. Related: Conference reports, Antiretrovirals, Side effects.
T20 is cost effective for UK purchasers
1 December 2003. Related: Conference reports, Antiretrovirals.
African patients and adherence in the UK
1 December 2003. Related: Conference reports, Antiretrovirals.
Five-year results of Kaletra-based therapy in treatment-naïve HIV patients
1 December 2003. Related: Conference reports, Antiretrovirals.
Rituximab plus CDE for HIV-related Non-Hodgkins Lymphoma (NHL)
1 December 2003. Related: Conference reports, Antiretrovirals, Cancer and HIV.
FTC (emtricitabine, Emtriva) approved in Europe
1 December 2003. Related: Antiretrovirals.
EMEA recommend approval for atazanavir for treatment experienced patients
1 December 2003. Related: Antiretrovirals.
Fosamprenavir (Lexiva) approved in US
1 December 2003. Related: Antiretrovirals.
US paediatric, adult and maternal-child guidelines updated
1 December 2003. Related: Antiretrovirals.
ddI may retain activity in nucleoside experienced patients
1 November 2003. Related: Conference reports, Antiretrovirals.
Studies and strategies with existing drugs
1 November 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Incremental progress with new antiviral drugs
1 November 2003. Related: Conference reports, Antiretrovirals.
Atazanavir ‘named-patient’ access extended in the UK and includes 150mg capsule
1 November 2003. Related: Antiretrovirals.
Another triple nuke failure: abacavir/ddI/d4T
1 November 2003. Related: Antiretrovirals.
FDA announces changes to ritonavir package insert
1 November 2003. Related: Antiretrovirals.
New atazanavir information
1 October 2003. Related: Conference reports, Antiretrovirals.
Boosted PI therapy antiretrovirals in treatment-experienced patients: SQV/r, ATV, ATV/r
1 October 2003. Related: Conference reports, Antiretrovirals.
Tenofovir, resistance and K65R and concomitant nucleosides
1 September 2003. Related: Conference reports, Antiretrovirals, Drug resistance.
Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir
1 September 2003. Related: Conference reports, Antiretrovirals, Weight, diabetes, metabolic complications.
Nevirapine and MTCT: the single-dose backlash
1 September 2003. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, Paediatric care.
Triple nucleoside combinations fail patients again
1 September 2003. Related: Conference reports, Antiretrovirals.
Nucleoside-sparing regimens
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual boosted PIs in salvage therapy
1 September 2003. Related: Conference reports, Antiretrovirals.
BMS reports on atazanavir efficacy and safety in treatment experienced patients
1 September 2003. Related: Conference reports, Antiretrovirals.
Unsupervised treatment interruptions are associated with increased risk of AIDS or death
1 September 2003. Related: Conference reports, Antiretrovirals.
Step-wise intervention eases diarrhoea linked to PI nelfinavir (Viracept) therapy
1 September 2003. Related: Conference reports, Antiretrovirals, Side effects.
Lessons learned from early HAART in acute HIV infection
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
CD4 cell reconstitution is significantly slower in older patients
1 September 2003. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Pharmacology studies at the 2nd IAS conference
1 September 2003. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
T-20 launched in UK
1 September 2003. Related: Antiretrovirals.
US approval of FTC (emtricitabine)
1 September 2003. Related: Antiretrovirals.
T-20 approved in Europe
1 July 2003. Related: Antiretrovirals.
Tenofovir European licence extended to include first-line therapy
1 July 2003. Related: Antiretrovirals.
FDA approves atazanavir in US – a once daily protease inhibitor
1 July 2003. Related: Antiretrovirals.
Atanazavir and saquinavir in salvage therapy: reduced effect on lipids shown in pilot study
1 July 2003. Related: Antiretrovirals.
Major change to OPTIMA salvage therapy study in the UK
1 July 2003. Related: Antiretrovirals.
New 625mg formulations of nelfinavir
1 June 2003. Related: Antiretrovirals.
Lopinavir suitable for TDM
1 June 2003. Related: Antiretrovirals.
Less diarrhoea and bioequivalence with the new nelfinavir 625mg tablet
1 May 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions, Side effects.
T-20 access programme to continue in UK for a further two months
1 May 2003. Related: Antiretrovirals.
Durability and success capability of HAART: 4.5 years follow-up
1 May 2003. Related: Antiretrovirals.
Older HIV-positive patients in the era of HAART: changing of a scenario
1 May 2003. Related: Antiretrovirals.
Immune reconstitution in older HIV-positive individuals
1 May 2003. Related: Antiretrovirals, Treatment strategies.
Pipeline compounds in Phase 2/3 Studies
1 April 2003. Related: Conference reports, Antiretrovirals.
96-week results show tenofovir-including regimen has side-effect advantages over d4T regimen in treatment naïve patients
1 April 2003. Related: Conference reports, Antiretrovirals.
2NN results – nevirapine and efavirenz in prospective randomised head-to-head study
1 April 2003. Related: Conference reports, Antiretrovirals.
NIH/NIAID study of generic drugs shows results consistent with stringent manufacturing standards
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment access, PK and drug interactions.
Treatment interruptions: cycles, pauses, are just plain stopping?
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Trizivir-only arm closed in PI-sparing, naïve therapy trial
1 April 2003. Related: Antiretrovirals, Other news.